Incro Pharmaceuticals, Denali Therapeutics deal

Denali acquired Incro, which was developing an undisclosed small molecule inhibitor of receptor-interacting serine-threonine kinase 1 ( RIPK1; RIP1) with CNS penetrant properties. Denali hopes the s...